Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Debt (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Total Debt for 4 consecutive years, with $127.8 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 29.3% to $127.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $127.8 million through Dec 2025, down 29.3% year-over-year, with the annual reading at $127.8 million for FY2025, 29.3% down from the prior year.
  • Total Debt hit $127.8 million in Q4 2025 for Axsome Therapeutics, down from $187.6 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $190.0 million in Q1 2025 to a low of $49.3 million in Q1 2022.
  • Historically, Total Debt has averaged $155.5 million across 4 years, with a median of $183.6 million in 2023.
  • Biggest five-year swings in Total Debt: soared 211.51% in 2023 and later fell 29.3% in 2025.
  • Year by year, Total Debt stood at $100.2 million in 2022, then skyrocketed by 84.18% to $184.5 million in 2023, then decreased by 2.04% to $180.7 million in 2024, then fell by 29.3% to $127.8 million in 2025.
  • Business Quant data shows Total Debt for AXSM at $127.8 million in Q4 2025, $187.6 million in Q3 2025, and $187.5 million in Q2 2025.